CT identifier
|
Drug
|
Method of action
|
Cancer
|
Approved/phase study
|
---|
Targeting T lymphocytes
|
NCT01844505
|
Nivolumab
|
Anti-PD1
|
mMM
|
Phase 3
|
NCT01642004
|
Nivolumab
|
Anti-PD1
|
NSCLC
|
Phase 3
|
NCT01354431
|
Nivolumab
|
Anti-PD1
|
mRCC
|
Phase 2
|
NCT00094653
|
Ipilimumab
|
Anti-CTLA4
|
mMM
|
Approved
|
NCT00861614
|
Ipilimumab
|
Anti-CTLA4
|
PC
|
Phase 3
|
NCT01450761
|
Ipilimumab
|
Anti-CTLA4
|
SCLC
|
Phase 3
|
NCT01285609
|
Ipilimumab
|
Anti-CTLA4
|
NSCLC
|
Phase 3
|
NCT01693783
|
Ipilimumab
|
Anti-CTLA4
|
Cervical cancer
|
Phase 2
|
NCT01860430
|
Ipilimumab
|
Anti-CTLA4
|
HNSCC
|
Phase 1B
|
NCT00257205
|
CP-675,206
|
Anti-CTLA4
|
mMM
|
Phase 3
|
Blocking immune cell recruitment
|
NCT01346358
|
IMC-CS4
|
CSFR1 antagonist
|
Advanced tumours
|
Phase 1
|
NCT01316822
|
ARRY-382
|
CSFR1 antagonist
|
Advanced tumours
|
Phase 1
|
NCT01015560
|
MLN1202
|
Anti-CCR2
|
Bone metastases
|
Phase 1
|
NCT01032122
|
Rituximab
|
Anti-CD20
|
mMM
|
Phase 1
|
NCT01376713
|
Ofatumumab
|
Anti-CD20
|
mMM
|
Phase 2
|
NCT01456585
|
CP-870,893
|
Anti-CD40
|
mPC
|
Phase 2
|
NCT01103635
|
CP-870,893
|
Anti-CD40
|
mMM
|
Phase 1
|
NCT00607048
|
CP-870,893
|
Anti-CD40
|
Solid tumours
|
Phase 1
|
Reprogramming immune cells
|
NCT00169104
|
G-CSF
|
Sustained neutrophilia
|
mBC
|
Phase 1/2
|
NCT00014456
|
G-CSF
| |
Solid tumours
|
Phase 1
|
NCT00070629
|
Promune
|
TLR9 agonist
|
NSCLC
|
Phase 2
|
NCT00043394
|
Promune
|
TLR9 agonist
|
BC
|
Phase 2
|
NCT00070642
|
Promune
|
TLR9 agonist
|
MM
|
Phase 2
|
NCT00043407
|
Promune
|
TLR9 agonist
|
RCC
|
Phase 1/2
|
NCT00292045
|
Promune
|
TLR9 agonist
|
PC
|
Phase 1
|
NCT00669292
|
Promune
|
TLR9 agonist
|
Esophageal cancer
|
Phase 1/2
|
Multiple
|
Vaccines (Multiple targets)
|
T-cell activation
|
Multiple cancers
| |
TH2-- > TH1 reprogramming
|
NCT01642290
|
Anti-OX40
|
Anti-OX40
|
mBC
|
Phase 1/2
|
NCT01644968
|
Anti-OX40
|
Anti-OX40
|
Advanced cancer
|
Phase 1
|
NCT01689870
|
Anti-OX40
|
Anti-OX40
|
mMM
|
Phase 1/2
|
- For an indepth review of the current landscape of targeting chronic inflammation, see Coussens [9]. CT identifier is to clinicaltrials.gov.
- Abbreviations: mMM metastatic malignant melanoma, NSCLC non-small cell lung cancer, mRCC metastatic renal cell carcinoma, PC prostate cancer, SCLC small-cell lung cancer, HNSCC head-and-neck squamous cell cancer, mBC metastatic breast cancer.